HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

States’ Restrictions On Sales Of Weight Loss OTCs, Supplements Stalled By Vetoes, Lobbying

Executive Summary

States’ efforts on prohibiting sales to minors of OTC diet drugs as well as weight loss and bodybuilding supplements to minors didn’t advance in 2022, setting stage for more showdowns in 2023.

You may also be interested in...



Age Restriction For Weight-Loss Supplement Sales Vetoed In California But Still In States' Crosshairs

“States need to now take notice and ensure these draconian policies never again see the light of day,” says NPA head Daniel Fabricant. CRN, neutral on restriction passed in California before governor’s veto, urges lawmakers to responsibly balance consumer safety with access to supplements.

US States On Verge Of Banning Weight-Loss Supplement Sales To Minors Without Prescription

Bills awaiting the signature of California and New York governors would set restrictions on sales of diet pills to minors and require a prescription to purchase them in those states.

US FDA Catches Up On Monograph Petitions: Denies Antiseptic TFM Requests Made In 2001

Agency’s recent responses denying three petitions filed in 2001 by US industry trade groups and in 2002 by pharmaceutical ingredient and chemicals firm explain the changes requested can be proposed in “OTC monograph order requests” pathway established in program overhaul.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel